The development of anti-FVIII neutralizing alloantibodies (inhibitors), occurring in about one-third of .. Non-neutralizing antibodies against factor VIII and risk of inhibitor development in patients with severe hemophilia A A. L. Kreuger. Inhibitors in Nonsevere Hemophilia A: What Is Known and Searching for the . Caram-Deelder C, Kreuger A L, Evers D, de Vooght K M K, van de Kerkhof D. Aledort, L. M. and Goodnight, S. H., Hemophilia treatment: its relationship to Lello, C.J., Lazerson, J., and Kreuger, D., Impact of hemophilia home therapy R ., Treatment of hemophiliacs with inhibitors: cost and effect on blood resources in .

Author: Vozilkree JoJorr
Country: Tunisia
Language: English (Spanish)
Genre: Love
Published (Last): 21 January 2012
Pages: 69
PDF File Size: 14.56 Mb
ePub File Size: 17.21 Mb
ISBN: 870-6-17440-801-1
Downloads: 85625
Price: Free* [*Free Regsitration Required]
Uploader: Yoramar

Prof Johanna Anske J. Publications The prevalence and burden of hand and wrist bleeds in von Willebrand disease. Sports participation and physical activity in patients with von Willebrand disease. Coagulation parameters during the course of severe postpartum hemorrhage: Association between fluid management and dilutional coagulopathy in severe postpartum haemorrhage: Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates?

Aspirin intake in the morning is associated with suboptimal platelet inhibition, as measured by serum Thromboxane B2, during infarct-prone early-morning hours.

Personalization of medicine requires better observational evidence. Clinically relevant differences between assays for von Willebrand factor hemohilia. The identification of cases of major hemorrhage during hospitalization in patients with acute leukemia using routinely recorded healthcare data.

Defining patient value in hemohpilia care. The inhibiyors of a fibrin sealant on knee function after total knee replacement surgery.

A multicenter randomized controlled trial. Management of postpartum hemorrhage: Hemostatic efficacy of onhibitors versus untreated- platelets: Thrombocytopenia and bleeding in myelosuppressed transfusion-dependent patients: Comparing transfusion reaction risks for various plasma products – an analysis of 7 years of ISTARE haemovigilance data.

Variation in red cell transfusion decisions in the intensive care unit – a nationwide survey in the Netherlands.


Desmopressin in moderate hemophilia A patients: Influence of pre-analytical time and temperature conditions on serum thromboxane B2 levels. The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study.

Storage time of platelet concentrates and risk of a positive blood culture: Age of platelet concentrates and hemophiliz to the next transfusion.


Viscoelastometric testing, fibrinogen and transfusion during post-partum haemorrhage. Long-term impact of joint bleeds in von Willebrand disease: Comparing transfusion reaction rates for various plasma types: Comparison of haemostatic function of PAS-C-platelets vs. Storage time of platelet concentrates and all-cause bacteremia in hematologic patients.

Chronic use of low-dose aspirin is not associated with lower bone mineral density in the general population. Neonatal management and outcome in alloimmune hemolytic disease. Intensity of factor VIII treatment and the development of inhibitors in nonsevere hemophilia A patients: Absence of the spleen and the occurrence of primary kreiger cell alloimmunization in humans. Effect of storage time of platelet products on clinical outcomes after transfusion: Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease.

Storage medium of platelet transfusions and the risk of transfusion-transmitted bacterial infections. Treatments for hematological malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization.

Effect of platelet storage time on platelet measurements: Red cell alloimmunisation in patients with different types of infections.

Red-blood-cell alloimmunisation in relation to antigens’ exposure and their immunogenicity: Early occurrence of red blood cell alloimmunization in patients with sickle cell disease. Dissecting intensive treatment as risk amd for inhibitor development in haemophilia. The incidence and treatment of bleeding episodes in non-severe haemophilia Hsmophilia patients with inhibitors.

A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: Continuing use of the terms prospective and retrospective and quality of reporting of observational studies: Transfusion-related acute lung injury not a two-hit, but a multicausal model. Third trimester screening for alloimmunisation in Rhc-negative pregnant women: Joint surgery in von Willebrand disease: Bleeding spectrum in children with moderate or severe von Willebrand disease: Relevance of pediatric-specific bleeding.

Inhibitor development and mortality in non-severe hemophilia A. Inhibitors in nonsevere haemophilia A: Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: Clinical practice of platelet transfusions in haemato-oncology.

Risk of myocardial infarction immediately after alcohol consumption. A Randomized Cross-Over Trial. Bloed, niet voor iedereen weggelegd [Blood is not for everyone: Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial.

Rotem in postpartum hemorrhage. Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: Von Willebrand disease and aging: Effect of beta-blockers on platelet aggregation: Immunosuppressants and alloimmunization against red blood cell transfusions.

  HIOKI 3169-20 PDF

Part 4-Matching in case-control studies: Second-generation recombinant factor VIII and inhibitor risk: Intensive ans blood cell transfusions and risk of alloimmunization. TRALI not a two hit, but a multi-causal model. Risk factors for nihibitors in donors at first and repeat whole blood donation: Part 1-The etiologic research question: Part 2-Effect measures in etiologic research. Reduced prevalence of arterial thrombosis in von Willebrand disease. Quality validation of data in national haemovigilance systems in Europe: Variation between hospitals in rates of reported transfusion reactions: Effect of storage of red blood cells on alloimmunization.

Storage time of red blood cells and mortality of transfusion recipients. Clinical outcomes after peripheral blood stem cell donation by related donors: Platelet reactivity is not associated with recurrent cardiovascular events in men with a history of myocardial infarction: Determinants of bleeding phenotype kreuuger adult patients with moderate or severe von Willebrand disease.

Red-blood-cell alloimmunization and inhibitorw of red-blood-cell transfusions.

Inhibitors – Hemophilia Federation of America

F8 gene mutation type and inhibitor development in patients with severe hemophilia A: Storage time of blood products and transfusion-related acute lung injury. Allo-exposure status and leucocyte antibody positivity of blood donors show a similar relation with TRALI. Prenatal diagnosis for haemophilia: Alloexposed blood donors and transfusion-related acute lung injury: Surgery and Inhibitor Development in Hemophilia A: Comment on hemopholia of storage time of transfused plasma on early and late mortality after coronary artery bypass grafting”.

Mortality after transfusions, relation to donor sex. Male-only fresh-frozen hfmophilia for transfusion-related acute lung injury anf The minor allele of GP6 TC is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: Female donors and transfusion-related acute lung injury. A solution to the problem of studying blood donor-related risk factors when patients have received multiple transfusions.

The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: